Will Moderna Stock Maintain Its Value in the Next 5 Years?

Investors shouldn't expect much COVID-related revenue

Moderna might see minimal COVID vaccine revenue in the next five years, as demand decreases and new competition emerges. Despite a sharp decline in sales, the company anticipates revenue from its RSV vaccine as part of its future strategy.

Moderna's operations will likely be broader

Expanding beyond COVID, Moderna is developing potential blockbuster vaccines and drugs, such as a personalized cancer vaccine and treatment for propionic acidemia. However, the timeline for revenue from these products is uncertain, making the long-term profitability of Moderna questionable.

Is Moderna's stock a good buy today?

Given the lack of groundbreaking products in its current pipeline, Moderna's stock may not be a wise investment at its current market cap. Although future developments could drive substantial growth, uncertainties persist around the company's revenue diversification and market performance.